The npj Breast Cancer study (Wang et al., 2026), an observational analysis of over 668,000 U.S. women from SEER data spanning 1975-2022, documents a troubling reversal: mortality improvements concentrated among older women while rates climbed for those under 50, especially Black, Hispanic, and Asian patients with triple-negative breast cancer. This large-scale retrospective cohort lacks RCT randomization but offers robust population-level power; no conflicts of interest are disclosed. Standard coverage emphasizes aggregate survival gains, missing how age, race, and molecular subtype interact to mask subgroup harm. Complementary evidence from the American Cancer Society's 2024 disparities report and a 2023 JAMA Oncology cohort study (n=92,000) confirms Black women under 50 face 1.8-fold higher triple-negative mortality, driven partly by later-stage diagnosis and treatment access gaps rather than screening alone. The original MedicalXpress summary underplays these systemic factors and the absence of age-stratified trials. Without interventions targeting these intersections, projected models from the NCI suggest a 15-20% further widening by 2035.